Measuring Acute Drug Demand in Humans (NCT05829655)

🧪 Interventions in This Study

• Drug A (Blinded Drug) (DRUG)
• Drug B (Blinded Drug) (DRUG)
• Drug C (Blinded Drug) (DRUG)
• Drug D (Blinded Drug) (DRUG)
• Suvorexant (20mg/day) (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• General Clinical Research Center — Baltimore, Maryland

📞 Contact the Study Coordinator

Phone: (667) 354-3516

Email: jstrickland@som.umaryland.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Opioid Use Disorder

• Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder — Atlantic City, New Jersey
• The Emergency Department Longitudinal Integrated Care — Seattle, Washington
• Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT — La Jolla, California
• Extended-release Buprenorphine as a Novel Low-dose Induction Strategy — Boston, Massachusetts
• Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial — Ann Arbor, Michigan
• Telemedicine XR-B for Individuals in Jail — Cumberland, Maryland

Explore by condition: All Opioid Use Disorder clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.